Study of Safety and Effectiveness of PoNS Device to Treat Chronic Balance Deficit Due to Traumatic Brain Injury (TBI)

January 30, 2020 updated by: Helius Medical Inc

Double Blind, Randomized, Sham Controlled Study of Safety and Effectiveness of the Portable Neuromodulation Stimulator (PoNS) Device for Cranial Nerve Noninvasive Neuromodulation Training for Chronic Balance Deficit Due to Mild/Moderate TBI

The purpose of this study is to determine if clinic and home training with a study device will improve a balance deficit. The study device is called Portable Neuromodulation Stimulator (PoNS). The study device will be placed on the tongue to deliver nerve stimulation. The study is testing if use of the study device in conjunction with physical therapy will improve balance and gait in patients suffering from a TBI. The effects of using the device and undergoing therapy will be measured using standardized tests of movement control, gait, headache and other TBI symptoms.

Study Overview

Study Type

Interventional

Enrollment (Actual)

122

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Quebec
      • Montreal, Quebec, Canada, H4A 3L5
        • The Montreal Neurofeedback Center
    • Florida
      • Orlando, Florida, United States, 32806
        • Orlando Health
    • Oregon
      • Portland, Oregon, United States, 97239
        • Oregon Health and Science University Center for Regenerative Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female, 18-65 years of age
  • Documentation on initial TBI (defined as closed-head, non-penetrating, blunt, whiplash, or explosive blast-induced brain injury) severity (at time of injury): Glasgow Coma Scale (GCS) score 9-15, with loss of consciousness < 24 hours, post-traumatic amnesia ≤7 days, or hospital admission ≤ 7 days post TBI
  • If female, subject is not pregnant, not lactating, has a negative pregnancy test prior to receipt of the PoNS™ device, and agrees to use contraception from screening to end of the study
  • Balance disorder with SOT composite score at least 16 points below normal resulting from a mild/moderate TBI without any concomitant pathologies
  • At least 1 year post injury
  • Stable neurologic status
  • Prior participation in a focused physical rehabilitation program for TBI and deemed by their treating clinician/themselves to have reached a plateau
  • Able to walk continuously on a treadmill for 20 minutes, level grade and at any speed, with support if needed
  • Access to a treadmill and commitment to utilize this for the at-home portion of the study
  • Able to understand the study procedures and give informed consent
  • Willing and able to adhere to the study schedule
  • Willing to complete a neuropsychological evaluation prior to inclusion

Exclusion Criteria:

  • Medical finding from screening history and physical examination that is clinically significant or would otherwise impact patient safety or data integrity
  • Medical finding from prior neuroradiologic study or recent MRI that is significant or that would impact patient safety or data integrity
  • Planned use or use of any investigational product, pharmaceutical or device within 30 days preceding receipt of the PoNS device and during the entire study
  • Balance or gait deficits due to lower extremity injury or neurological condition other than TBI
  • Penetrating brain injury, craniotomy or refractory subdural hematoma
  • Oral health problems at the time of recruitment
  • Oral surgery within 3 months of screening
  • History of oral cancer
  • Non-removable metal orthodontic devices that could interfere with PoNS use
  • Presence of metallic implant or other MRI-incompatible device
  • Blood pressure abnormalities considered clinically significant
  • Use of Coumadin or other anticoagulant except aspirin in the last 6 months
  • Untreated or undiagnosed diabetes
  • Diabetic neuropathy
  • Active or recent (within 1 year) treatment for any cancer, excluding basal cell carcinoma.
  • Neurological disorders other than those attributed to the primary diagnosis (neurodegenerative diseases such as Multiple Sclerosis, Parkinson's disease, Alzheimer's disease or other dementia, Amyotrophic Lateral Sclerosis)
  • History of epileptic or other seizure disorders
  • Known ischemic heart disease and/or history or atrial or ventricular arrhythmias with or without syncope
  • Any other untreated or unstable acute or chronic, clinically significant medical condition for which the subject is currently undergoing treatment that the study investigator deems unsuitable for inclusion
  • Use of a lower extremity biomechanical prosthetic with the exception of a splint for foot drop
  • Females who are pregnant, lactating, or planning to become pregnant during the study
  • Chronic use of any potentially interfering medication, or use of any medication that would compromise the ability to function or perform the study activities
  • Addition of and/or major change in type or dosage of any prescription medication within 3 months prior to receipt of the PoNS device
  • Active alcoholism. The study investigator will have the right to exclude subject participation if the subject seems intoxicated at time of screening and/or during any study appointment.
  • History of drug abuse will be assessed
  • Recent history of smokeless tobacco use
  • Any reason that may be a threat to health or safety
  • Any finding in the neuropsychological evaluation that makes the subject unsuitable for inclusion

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PoNS Device
Cranial nerve non-invasive neuromodulation via PoNS device. The system delivers 19 V pulses to the tongue (a nominal 5.5 kilo-ohm load).
The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
Sham Comparator: Sham PoNS Device
The sham control device appears physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, thereby providing minimal, if any, cranial nerve non-invasive neuromodulation via PoNS device
The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. The sham control device is physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, minimizing any neuromodulatory effect. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Response to treatment defined as an 8 point change in the Sensory Organization Test (SOT) from baseline
Time Frame: 5 weeks after the start of the intervention
The SOT is an objective, automated measure of sensory-motor integration that evaluates the functional contribution of the somatosensory, visual, and vestibular components of balance. A composite score is calculated and compared with a database normalized for age and height.
5 weeks after the start of the intervention

Secondary Outcome Measures

Outcome Measure
Time Frame
Increase in SOT score from pre-training SOT score at the end of 2 weeks in lab training
Time Frame: Two weeks after start of the intervention
Two weeks after start of the intervention

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of falls
Time Frame: Daily for 5 weeks
Daily for 5 weeks
Frequency of headaches
Time Frame: 5 weeks
Frequency of headaches will be assessed using the headache disability index
5 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2015

Primary Completion (Actual)

August 18, 2017

Study Completion (Actual)

August 18, 2017

Study Registration Dates

First Submitted

April 20, 2015

First Submitted That Met QC Criteria

April 23, 2015

First Posted (Estimate)

April 29, 2015

Study Record Updates

Last Update Posted (Actual)

February 7, 2020

Last Update Submitted That Met QC Criteria

January 30, 2020

Last Verified

January 1, 2020

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Traumatic Brain Injury

Clinical Trials on Cranial nerve non-invasive neuromodulation via PoNS device

3
Subscribe